title: Leukocyte traffic blockade as a therapeutic strategy in inflammatory bowel disease.
abstract: Dysregulated recruitment of leukocytes into the intestine is a characteristic feature of IBD. Several families of molecules regulate the influx of these cells into sites of inflammation within the gastrointestinal tract. Pharmacological blockade of interactions between molecules that mediate the formation of stable bonds (integrins) and their endothelial ligands has already shown clinical efficacy. Antibodies that target participant molecules have been approved by the US Federal Drug Administration for use in Crohn's, multiple sclerosis (MS) (i.e. natalizumab) and psoriasis (i.e. efalizumab). A more recent additional family of drugs, which might also interfere with lymphocyte traffic (i.e. sphingosine-1- phosphate receptor agonists: fingolimod) is in clinical use for MS and just recently entered the clinical trial stage for ulcerative colitis. In the present review we discuss basic aspects of clinically relevant molecules and compile the clinical studies that support the targeting of specific steps of the leukocyte adhesion cascade for therapeutic purposes in IBD.
authors.affiliation: Inflammatory Bowel Disease Center, Division of Gastroenterology, 9500 Gilman Drive, San Diego, California 92093-0063, USA. Jriveranieves@ucsd.edu.
authors.forename: Giorgos
authors.initials: G
authors.lastname: Bamias
authors.forename: David J
authors.initials: DJ
authors.lastname: Clark
authors.forename: Jesús
authors.initials: J
authors.lastname: Rivera-Nieves
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use*; D002448:Cell Adhesion / Q000187:drug effects* / Q000276:immunology; D002465:Cell Movement / Q000187:drug effects / Q000276:immunology; D002986:Clinical Trials as Topic; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology / Q000627:therapeutic use*; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy* / Q000473:pathology*; D007413:Intestinal Mucosa / Q000276:immunology / Q000473:pathology; D007962:Leukocytes / Q000187:drug effects* / Q000276:immunology; D058990:Molecular Targeted Therapy; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents